AveXis, Inc.
(NASDAQ : AVXS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.08%109.411.1%$637.77m
GILDGilead Sciences, Inc.
1.66%75.570.9%$577.68m
AMGNAmgen Inc.
1.13%176.901.1%$506.89m
REGNRegeneron Pharmaceuticals, Inc.
1.52%388.952.7%$352.74m
BIIBBiogen Inc.
1.36%327.941.2%$335.33m
ALXNAlexion Pharmaceuticals, Inc.
2.36%115.761.9%$262.11m
VRTXVertex Pharmaceuticals Incorporated
2.34%145.861.9%$218.93m
BLUEBluebird Bio, Inc.
-0.76%182.9516.1%$207.25m
ILMNIllumina, Inc.
2.70%216.553.5%$180.07m
ALNYAlnylam Pharmaceuticals, Inc
1.56%125.5910.0%$167.77m
AAgilent Technologies, Inc.
1.64%67.601.5%$158.47m
NKTRNektar Therapeutics
3.36%56.906.1%$157.89m
INCYIncyte Corporation
0.46%96.412.5%$142.11m
BMRNBioMarin Pharmaceutical Inc.
5.07%93.024.4%$114.48m
JUNOJuno Therapeutics, Inc.
1.16%44.6813.5%$102.38m

Company Profile

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.